Alder Biopharmaceuticals competitors

Rick joined Alimera Sciences in 2005 as CFO and assumed the position of COO in 2010. He is responsible for strategic finance, accounting, distribution logistics, human resources and information technology. Rick brings a wealth of financial and operational management experience with both public and private ventures to the team. Since joining Alimera, he completed three rounds of venture funding totaling approximately $67 million. In 2010 Rick led Alimera's successful IPO, raising $72 million, and negotiated a $32.5 million credit facility leading to recognition of Alimera as the \'Strategic Deal of the Year\' by both Southeastern BIO and Georgia BIO. Rick currently serves as the chairman of the board of directors and audit committee of Jones Soda Co., a Seattle-based publicly traded company, and vice-chairman of the North Metro Miracle League, an Atlanta-based charitable organization. Rick has been active in Atlanta business for more than 20 years, with experience that includes financial and accounting management, mergers and acquisitions, and initial public offerings, as well as entrepreneurial and start-up operational activities. Rick is the founder of two consulting practices, Brand Ignition Group and Black River Holdings, Inc. He is also the former chief financial officer and senior executive vice president of Netzee, Inc., a provider of internet banking solutions to community banks that went public in 1999. Rick started his career in Arthur Andersen’s audit and business advisory practice where he was a senior manager and a certified public accountant. He has an accounting degree from Wake Forest University.

Hamza Suri is a President & CEO at AnaptysBio Inc.

Nick Leschly has served as our chief bluebird since September 2010. Formerly, Nick was a partner and founding member of Third Rock Ventures in 2007. Nick played an integral role in the overall formation, development and business strategy of several of Third Rock’s portfolio companies, including Agios Pharmaceuticals, Inc. and Edimer Pharmaceuticals, Inc. Prior to joining Third Rock, he worked at Millennium Pharmaceuticals, leading several early-stage drug development programs and served as the product leader for VELCADE. Nick also founded and served as chief executive officer of MedXtend Corporation. He received his B.S. in molecular biology from Princeton University and his MBA from Wharton Business School. He currently serves as a board member of the Biotechnology Innovation Organization (BIO) and Synlogic Therapeutics.

Gregory A. Demopulos, M.D. is one of our founders and has served as our President, Chief Executive Officer and Chairman of the Board of Directors since June 1994. Prior to founding Omeros, Dr. Demopulos completed his residency in orthopedic surgery at Stanford University and his fellowship training at Duke University. Dr. Demopulos received his M.D. from the Stanford University School of Medicine and his B.S. from Stanford University.

Founder Aedio • Worked at @massachusetts-general-hospital-mgh, @brigham-women-s-hospital • Studied at @tufts-university

Cameron Durrant is a Chairman, CEO and Interim CFO at Humanigen Inc and is based in Brisbane, California.